Journal of Evidence-Based Dental Practice
Volume 9, Issue 1 , Pages 13-15, March 2009

Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly

Professor, Oral Medicine, NSU College of Dental Medicine, 3200 S. University Drive, Fort Lauderdale, FL 33328

Article Title and Bibliographic Information

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

Grbic JT, et al.

J Am Dent Assoc 2008;139(1):32-40.

Level of Evidence

Level 3: Other evidence.

Strength Of Recommendation Grade

Grade C: Consensus, disease-oriented evidence, usual practice, expert opinion, or case series for studies of diagnosis, treatment, prevention or screening.

Purpose/Question

What is the incidence of ONJ in women with osteoporosis who received once-yearly infusion of 5 mg of zoledronic acid?

Source of Funding

Novartis Pharma AG, Basel, Switzerland, provided financial support and the zoledronic acid used in this study.

Type of Study/Design

Three-year international multicenter, randomized, double-blind, placebo-controlled clinical trial.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 20.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1532-3382(08)00226-1

doi:10.1016/j.jebdp.2008.12.014

Journal of Evidence-Based Dental Practice
Volume 9, Issue 1 , Pages 13-15, March 2009

Article Tools